Biota Pharmaceuticals to Host Conference Call to Report Second Quarter Fiscal Year 2015 Financial Results on February 5, 2015...
January 29 2015 - 2:00PM
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company"), a
biopharmaceutical company focused on the discovery and development
of products to prevent and treat serious and potentially
life-threatening viral respiratory infectious diseases, announced
today that management will host a conference call on Thursday,
February 5, 2015 at 9:00 a.m. EST to review the Company's second
quarter financial results and provide an update on recent corporate
developments. The Company will issue a press release summarizing
its financial results the same day, prior to the conference call.
In order to participate in the conference call, please dial
(877) 312-5422 (domestic) or (253) 237-1122 (international). The
live webcast can be accessed under the Investors section of the
Company's website at www.biotapharma.com or you may use the link:
http://edge.media-server.com/m/p/tqxvzn68.
About Biota Pharmaceuticals, Inc.
Biota Pharmaceuticals, Inc. is a company focused on the
discovery and development of products to treat serious viral
respiratory infectious diseases. The Company currently has two
clinical-stage Phase 2 product candidates: (i) laninamivir
octanoate, which is being developed as a one-time treatment for
influenza A and B infections; and (ii) vapendavir, a potent, broad
spectrum capsid inhibitor of enteroviruses in development for the
treatment of human rhinovirus infected patients with underlying
respiratory illnesses, such as moderate-to-severe asthma and
chronic obstructive pulmonary disease (COPD). The Company is also
conducting IND-enabling studies with BTA-C585, an orally
bioavailable F protein inhibitor, in development for the treatment
of respiratory syncytial virus infections. For additional
information about the Company, please visit
www.biotapharma.com.
Biota is a registered trademark of Biota Pharmaceuticals,
Inc.
CONTACT: Joseph M. Patti, PhD
President and Chief Executive Officer
(678) 221-3351
j.patti@biotapharma.com
Sarah McCabe
Stern Investor Relations, Inc.
(267) 909-9237
sarah@sternir.com
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Apr 2024 to May 2024
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From May 2023 to May 2024